(object) array( 'id' => '10479591', 'url' => 'FR/actinic_keratoses_₂', 'image' => '', 'title' => 'Kératose actinique', 'tags' => array ( 0 => 'Kératose actinique', 1 => 'Beauty', 2 => 'Skin care', 3 => '', ), 'term' => 'Kératose actinique', 'source_id' => 5092398, 'type' => 'term', 'namespace' => 1244, 'nstext' => 'FR', 'industry' => array ( 0 => 'Beauty', ), 'category' => array ( 0 => 'Skin care', ), 'lastedit' => '20150728083418', 'part_of_speech' => 'noun', 'creation_user' => 'LinguaDiligence', 'special_term' => '', 'definition' => 'Lésions précancéreuses se traduisant par une zone rouge, épaisse et rugueuse ; elles apparaissent habituellement sur une peau endommagée par le soleil.', 'usage_comment' => '', 'glossary' => '', 'width' => 0, 'height' => 0, '_version_' => 1507928310838984706, 'nstext_full' => 'French (FR)', 's_attr' => (object) array( 'Definition' => 'Precancerous growths that can appear red, thick, and rough; usually found on sun-damaged skin.', 'Part of Speech' => 'noun', 'Industry' => 'Beauty', 'Product Category' => 'Skin care', 'Creation User' => 'MaryK', 'Creation Date' => '2013/3/15', 'Term' => 'actinic keratoses', 'Source Lang' => '1180', ), 's_namespace_text' => 'EN', 's_namespace_text_full' => 'English (EN)', 's_title' => 'actinic_keratoses_₂', )

(object) array( 'id' => '5178801', 'url' => 'FR/treatment-naive_₁', 'image' => '', 'title' => 'Patient naïf de traitement', 'tags' => array ( 0 => 'Patient naïf de traitement', 1 => 'Pharmaceutical', 2 => 'Drugs', 3 => 'Tylenol', 4 => '', ), 'term' => 'Patient naïf de traitement', 'source_id' => 3284753, 'type' => 'term', 'namespace' => 1244, 'nstext' => 'FR', 'industry' => array ( 0 => 'Pharmaceutical', ), 'category' => array ( 0 => 'Drugs', ), 'product' => array ( 0 => 'Tylenol', ), 'lastedit' => '20150721112814', 'part_of_speech' => 'adjective', 'creation_user' => 'LinguaDiligence', 'special_term' => '', 'definition' => '\'Patient naïf de traitement\' ou \'Patient naïf de médicaments\' se réfère à quelqu\'un n\'ayant encore jamais pris de traitement contre le VIH. Quelqu\'un qui prend déjà des médicaments est appelé \'patient déjà sous traitement\'.', 'usage_comment' => '', 'glossary' => '', 'width' => 0, 'height' => 0, '_version_' => 1507305079942676480, 'nstext_full' => 'French (FR)', 's_attr' => (object) array( 'Term' => 'treatment-naive', 'Definition' => '‘Treatment-naive’ or ‘drug naive’ refers to someone who has never used HIV drugs. Someone who has used drugs before is called ‘treatment-experienced’.', 'Part of Speech' => 'adjective', 'Usage Status' => 'New', 'Industry' => 'Pharmaceutical', 'Product Category' => 'Drugs', 'Product' => 'Tylenol', 'Creation User' => 'Chiara conte', 'Creation Date' => '2012/6/29', 'Source Lang' => '1180', ), 's_namespace_text' => 'EN', 's_namespace_text_full' => 'English (EN)', 's_title' => 'treatment-naive_₁', )

(object) array( 'id' => '7745836', 'url' => 'FR/informed_consent_₇', 'image' => '', 'title' => 'Consentement éclairé', 'tags' => array ( 0 => 'Consentement éclairé', 1 => 'Pharmaceutical', 2 => 'Clinical trials', 3 => '', ), 'term' => 'Consentement éclairé', 'source_id' => 1259720, 'type' => 'term', 'namespace' => 1244, 'nstext' => 'FR', 'industry' => array ( 0 => 'Pharmaceutical', ), 'category' => array ( 0 => 'Clinical trials', ), 'lastedit' => '20150721084111', 'part_of_speech' => 'noun', 'creation_user' => 'LinguaDiligence', 'special_term' => '', 'definition' => 'Un processus afin de s\'assurer que les patients volontaires comprennent tous les risques associés à la participation à un essai clinique tels que les effets indésirables et choisissent de participer sans coercition ni pression de quiconque. Le chercheur principal ou de ses associés sont tenus d\'expliquer l\'étude attentivement et répondre à toutes les questions d\'un participant avant l\'essai clinique.', 'usage_comment' => '', 'glossary' => '', 'width' => 0, 'height' => 0, '_version_' => 1507294573052821505, 'nstext_full' => 'French (FR)', 's_attr' => (object) array( 'Term' => 'informed consent', 'Definition' => 'A process to ensure that patient volunteers understand all the risks associated participating in a clinical trial such as adverse side effects and are choosing to participate without coercion or pressure from anyone. The principal investigator or his or her associates are required to explain the study carefully and answer all questions of a participant before the clinical trial.', 'Part of Speech' => 'noun', 'Usage Status' => 'New', 'Industry' => 'Pharmaceutical', 'Product Category' => 'Clinical trials', 'Creation User' => 'John Martin', 'Creation Date' => '2011/5/16', 'Source Lang' => '1180', ), 's_namespace_text' => 'EN', 's_namespace_text_full' => 'English (EN)', 's_title' => 'informed_consent_₇', )

(object) array( 'id' => '6229091', 'url' => 'FR/study_design', 'image' => '', 'title' => 'Plan d\'étude', 'tags' => array ( 0 => 'Plan d\'étude', 1 => 'Medical devices', 2 => 'Pharmaceutical', 3 => 'Clinical trials', 4 => 'National Library of Medicine', 5 => '', ), 'term' => 'Plan d\'étude', 'source_id' => 4011443, 'type' => 'term', 'namespace' => 1244, 'nstext' => 'FR', 'industry' => array ( 0 => 'Medical devices', 1 => 'Pharmaceutical', ), 'category' => array ( 0 => 'Clinical trials', ), 'company' => array ( 0 => 'National Library of Medicine', ), 'lastedit' => '20150727104709', 'part_of_speech' => 'noun', 'creation_user' => 'LinguaDiligence', 'special_term' => '', 'definition' => 'Les méthodes d\'investigation utilisées dans l\'étude clinique. Pour les études interventionnelles, celles-ci incluent un objectif principal, un modèle d\'intervention, en insu ou en aveugle, et une affectation.', 'usage_comment' => '', 'glossary' => '', 'width' => 0, 'height' => 0, '_version_' => 1507846081754431489, 'nstext_full' => 'French (FR)', 's_attr' => (object) array( 'Company' => 'National Library of Medicine', 'Definition' => 'The investigative methods used in the clinical study. For interventional studies, these include primary purpose, intervention model , masking or blinding, and allocation.', 'Industry' => 'Medical devices; Pharmaceutical', 'Part of Speech' => 'noun', 'Product Category' => 'Clinical trials', 'Creation User' => 'elighy', 'Creation Date' => '2012/10/13', 'Term' => 'study design', 'Source Lang' => '1180', ), 's_namespace_text' => 'EN', 's_namespace_text_full' => 'English (EN)', 's_title' => 'study_design', )

(object) array( 'id' => '7745840', 'url' => 'FR/experimental_treatment', 'image' => '', 'title' => 'Traitement expérimental', 'tags' => array ( 0 => 'Traitement expérimental', 1 => 'Pharmaceutical', 2 => 'Clinical trials', 3 => '', ), 'term' => 'Traitement expérimental', 'source_id' => 1259724, 'type' => 'term', 'namespace' => 1244, 'nstext' => 'FR', 'industry' => array ( 0 => 'Pharmaceutical', ), 'category' => array ( 0 => 'Clinical trials', ), 'lastedit' => '20150721084114', 'part_of_speech' => 'noun', 'creation_user' => 'LinguaDiligence', 'special_term' => '', 'definition' => 'Le nouveau médicament ou thérapie testé dans l\'essai clinique.', 'usage_comment' => '', 'glossary' => '', 'width' => 0, 'height' => 0, '_version_' => 1507294573052821507, 'nstext_full' => 'French (FR)', 's_attr' => (object) array( 'Term' => 'experimental treatment', 'Definition' => 'The new drug or therapy being tested in the clinical trial.', 'Part of Speech' => 'noun', 'Usage Status' => 'New', 'Industry' => 'Pharmaceutical', 'Product Category' => 'Clinical trials', 'Creation User' => 'John Martin', 'Creation Date' => '2011/5/16', 'Source Lang' => '1180', ), 's_namespace_text' => 'EN', 's_namespace_text_full' => 'English (EN)', 's_title' => 'experimental_treatment', )

(object) array( 'id' => '6227397', 'url' => 'FR/exclusion_criteria_₁', 'image' => '', 'title' => 'Critères d\'exclusion', 'tags' => array ( 0 => 'Critères d\'exclusion', 1 => 'Medical devices', 2 => 'Pharmaceutical', 3 => 'Clinical trials', 4 => 'National Library of Medicine', 5 => '', ), 'term' => 'Critères d\'exclusion', 'source_id' => 4010892, 'type' => 'term', 'namespace' => 1244, 'nstext' => 'FR', 'industry' => array ( 0 => 'Medical devices', 1 => 'Pharmaceutical', ), 'category' => array ( 0 => 'Clinical trials', ), 'company' => array ( 0 => 'National Library of Medicine', ), 'lastedit' => '20150722105910', 'part_of_speech' => 'noun', 'creation_user' => 'LinguaDiligence', 'special_term' => '', 'definition' => 'Les facteurs ou les raisons qui empêchent une personne de participer à une étude clinique.', 'usage_comment' => '', 'glossary' => '', 'width' => 0, 'height' => 0, '_version_' => 1507393851744059394, 'nstext_full' => 'French (FR)', 's_attr' => (object) array( 'Company' => 'National Library of Medicine', 'Definition' => 'The factors or reasons that prevent a person from participating in a clinical study.', 'Industry' => 'Medical devices; Pharmaceutical', 'Part of Speech' => 'noun', 'Product Category' => 'Clinical trials', 'Creation User' => 'elighy', 'Creation Date' => '2012/10/13', 'Term' => 'exclusion criteria', 'Source Lang' => '1180', ), 's_namespace_text' => 'EN', 's_namespace_text_full' => 'English (EN)', 's_title' => 'exclusion_criteria_₁', )

(object) array( 'id' => '7745593', 'url' => 'FR/study_coordinator', 'image' => '', 'title' => 'Coordinateur de l\'étude clinique', 'tags' => array ( 0 => 'Coordinateur de l\'étude clinique', 1 => 'Pharmaceutical', 2 => 'Clinical trials', 3 => '', ), 'term' => 'Coordinateur de l\'étude clinique', 'source_id' => 1259718, 'type' => 'term', 'namespace' => 1244, 'nstext' => 'FR', 'industry' => array ( 0 => 'Pharmaceutical', ), 'category' => array ( 0 => 'Clinical trials', ), 'lastedit' => '20150721084111', 'part_of_speech' => 'noun', 'creation_user' => 'LinguaDiligence', 'special_term' => '', 'definition' => 'Un membre du personnel qui, travaillant pour l\'investigateur principal, contacte les patients par rapport à l\'inscription à l\'étude, planifie les rendez-vous, maintient les registres nécessaires et gère le fonctionnement quotidien de l\'étude.', 'usage_comment' => '', 'glossary' => '', 'width' => 0, 'height' => 0, '_version_' => 1507294573052821504, 'nstext_full' => 'French (FR)', 's_attr' => (object) array( 'Term' => 'study coordinator', 'Definition' => 'A staff person who works for the principal investigator to contact patients about enrolling in the study, schedule appointments, maintain required records and manage the day-to-day operation of the study.', 'Part of Speech' => 'noun', 'Usage Status' => 'New', 'Industry' => 'Pharmaceutical', 'Product Category' => 'Clinical trials', 'Creation User' => 'John Martin', 'Creation Date' => '2011/5/16', 'Source Lang' => '1180', ), 's_namespace_text' => 'EN', 's_namespace_text_full' => 'English (EN)', 's_title' => 'study_coordinator', )

(object) array( 'id' => '8442002', 'url' => 'FR/thiomersal', 'image' => 'Vaccines with thiomersal.jpg;', 'title' => 'Thiomersal', 'tags' => array ( 0 => 'Thiomersal', 1 => 'Pharmaceutical', 2 => 'Vaccines', 3 => '', ), 'term' => 'Thiomersal', 'source_id' => 274263, 'type' => 'term', 'namespace' => 1244, 'nstext' => 'FR', 'industry' => array ( 0 => 'Pharmaceutical', ), 'category' => array ( 0 => 'Vaccines', ), 'lastedit' => '20150721084102', 'part_of_speech' => 'noun', 'creation_user' => 'LinguaDiligence', 'special_term' => '', 'definition' => 'Le thimérosal est un conservateur contenant du mercure qui est souvent utilisé dans les vaccins en raison de ses propriétés antiseptiques et antifongiques. L\'utilisation du thimérosal comme conservateur de vaccin a été controversée au cours des dernières années en raison du risque potentiellement accru de provoquer l\'autisme chez les enfants. Cependant, la dernière étude du CDC a toutefois montré qu\'aucun lien n\'avait été trouvé entre le thimérosal et l\'autisme.', 'usage_comment' => '', 'glossary' => '', 'width' => 485, 'height' => 385, '_version_' => 1507294573052821508, 'nstext_full' => 'French (FR)', 's_attr' => (object) array( 'Term' => 'thiomersal', 'Definition' => 'Thimerosal is a mercury-based preservative that is often used in vaccines because of its antiseptic and antifungal properties. The use of thimerosal as a vaccine preservative has been controversial in recent years due to potentially increased risk of causing children\'s autism. However, the latest CDC study however showed no link found between thimerosal and autism', 'Part of Speech' => 'noun', 'Usage Status' => 'New', 'Synonym' => '', 'Sample Image' => 'Vaccines with thiomersal.jpg;', 'Industry' => 'Pharmaceutical', 'Product Category' => 'Vaccines', 'Domain' => 'Documentation; Marketing', 'Other Reference' => 'TIN', 'Creation User' => 'Williamb', 'Creation Date' => '2010/9/13', 'Source Lang' => '1180', ), 's_namespace_text' => 'EN', 's_namespace_text_full' => 'English (EN)', 's_title' => 'thiomersal', )

(object) array( 'id' => '6877605', 'url' => 'FR/Angiotensin_II_Receptor_Blockers_(ARBs)', 'image' => '', 'title' => 'Antagonistes des récepteurs de l\'angiotensine II (ARA II)', 'tags' => array ( 0 => 'Antagonistes des récepteurs de l\'angiotensine II (ARA II)', 1 => 'Pharmaceutical', 2 => 'Drugs', 3 => '', ), 'term' => 'Antagonistes des récepteurs de l\'angiotensine II (ARA II)', 'source_id' => 1038764, 'type' => 'term', 'namespace' => 1244, 'nstext' => 'FR', 'industry' => array ( 0 => 'Pharmaceutical', ), 'category' => array ( 0 => 'Drugs', ), 'lastedit' => '20150721084107', 'part_of_speech' => 'proper noun', 'creation_user' => 'LinguaDiligence', 'special_term' => '', 'definition' => 'Médicaments qui bloquent l\'action de l\'angiotensine II en l\'empêchant de se lier à des récepteurs de l\'angiotensine II sur les vaisseaux sanguins.', 'usage_comment' => '', 'glossary' => '', 'width' => 0, 'height' => 0, '_version_' => 1507294573051772930, 'nstext_full' => 'French (FR)', 's_attr' => (object) array( 'Term' => 'Angiotensin II Receptor Blockers (ARBs)', 'Definition' => 'Medications that block the action of angiotensin II by preventing angiotensin II from binding to angiotensin II receptors on blood vessels.', 'Part of Speech' => 'proper noun', 'Usage Status' => 'New', 'Industry' => 'Pharmaceutical', 'Product Category' => 'Drugs', 'Creation User' => 'CCTRADUCTION', 'Creation Date' => '2011/4/12', 'Source Lang' => '1180', ), 's_namespace_text' => 'EN', 's_namespace_text_full' => 'English (EN)', 's_title' => 'Angiotensin_II_Receptor_Blockers_(ARBs)', )

(object) array( 'id' => '6227764', 'url' => 'FR/sponsor_investigator', 'image' => '', 'title' => 'Sponsor-investigateur', 'tags' => array ( 0 => 'Sponsor-investigateur', 1 => 'Medical devices', 2 => 'Pharmaceutical', 3 => 'Clinical trials', 4 => 'National Library of Medicine', 5 => '', ), 'term' => 'Sponsor-investigateur', 'source_id' => 4010894, 'type' => 'term', 'namespace' => 1244, 'nstext' => 'FR', 'industry' => array ( 0 => 'Medical devices', 1 => 'Pharmaceutical', ), 'category' => array ( 0 => 'Clinical trials', ), 'company' => array ( 0 => 'National Library of Medicine', ), 'lastedit' => '20150722105912', 'part_of_speech' => 'noun', 'creation_user' => 'LinguaDiligence', 'special_term' => '', 'definition' => 'La personne qui initie et conduit l\'étude clinique.', 'usage_comment' => '', 'glossary' => '', 'width' => 0, 'height' => 0, '_version_' => 1507393851745107968, 'nstext_full' => 'French (FR)', 's_attr' => (object) array( 'Company' => 'National Library of Medicine', 'Definition' => 'The person who both initiates and conducts the clinical study.', 'Industry' => 'Medical devices; Pharmaceutical', 'Part of Speech' => 'noun', 'Product Category' => 'Clinical trials', 'Creation User' => 'elighy', 'Creation Date' => '2012/10/13', 'Term' => 'sponsor investigator', 'Source Lang' => '1180', ), 's_namespace_text' => 'EN', 's_namespace_text_full' => 'English (EN)', 's_title' => 'sponsor_investigator', )